There is insufficient evidence that testing patients for cytochrome P450 gene mutations with Roche’s AmpliChip or other platforms can help physicians treat depression with selective serotonin reuptake inhibitors, the Evaluation of Genomic Applications in Practice and Prevention Working Group has found.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.